Status:

COMPLETED

Safety Study of a Bioresorbable Coronary Stent

Lead Sponsor:

REVA Medical, Inc.

Conditions:

Myocardial Ischemia

Coronary Artery Stenosis

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

To evaluate the safety of a new bioresorbable (non-permanent) stent platform in native coronary arteries.

Detailed Description

Today, coronary artery disease is often treated by placing a metal stent inside the vessel that serves as a permanent scaffold. However, it is hypothesized that the stent is no longer needed once the ...

Eligibility Criteria

Inclusion

  • Evidence of myocardial ischemia or a positive functional study.
  • Normal CK-MB.
  • Target lesion must be located in a native coronary artery where target vessel diameter is ≥ 2.9 mm and ≤ 3.3 mm and target lesion length is ≤ 12 mm, both assessed by on-line QCA and IVUS
  • Target lesion must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and \< 100% with a TIMI flow of ≥ 2.
  • Staged procedures are allowed in non-target vessels \>24 hours before or \> 30 days after REVA stent implantation

Exclusion

  • A myocardial infarction (CK-MB or Troponin \> 3 times normal) within 72 hours of the procedure, has signs or symptoms of an ongoing myocardial infarction or has any visible thrombus
  • Unprotected left main coronary disease with \>50% stenosis
  • The target vessel is totally occluded (TIMI Flow 0 to 1)
  • Target lesion involves a bifurcation (a lesion with a side branch \>2.0 mm in diameter containing a \>50% stenosis)
  • Target lesion is located within a segment supplied by distal graft
  • Target lesion has possible or definite thrombus

Key Trial Info

Start Date :

December 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2018

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT01262703

Start Date

December 1 2011

End Date

December 1 2018

Last Update

March 29 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Instituto Dante Pazzanese de Cardiologia

São Paulo, Brazil